HRP20110470T1 - Inhibitori proteinskih kinaza - Google Patents
Inhibitori proteinskih kinaza Download PDFInfo
- Publication number
- HRP20110470T1 HRP20110470T1 HR20110470T HRP20110470T HRP20110470T1 HR P20110470 T1 HRP20110470 T1 HR P20110470T1 HR 20110470 T HR20110470 T HR 20110470T HR P20110470 T HRP20110470 T HR P20110470T HR P20110470 T1 HRP20110470 T1 HR P20110470T1
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- 6alkyl
- image
- halogen
- optionally substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 38
- 108091007914 CDKs Proteins 0.000 claims abstract 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims abstract 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 208000035473 Communicable disease Diseases 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims abstract 2
- 208000026278 immune system disease Diseases 0.000 claims abstract 2
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 230000002062 proliferating effect Effects 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims 36
- 150000002367 halogens Chemical class 0.000 claims 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 23
- 125000001424 substituent group Chemical group 0.000 claims 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 11
- 125000004970 halomethyl group Chemical group 0.000 claims 10
- 125000004452 carbocyclyl group Chemical group 0.000 claims 9
- -1 methoxy, ethoxy Chemical group 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 5
- 238000006482 condensation reaction Methods 0.000 claims 5
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99882107P | 2007-10-12 | 2007-10-12 | |
| PCT/EP2008/063715 WO2009047359A1 (fr) | 2007-10-12 | 2008-10-13 | Inhibiteurs de protéine kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110470T1 true HRP20110470T1 (hr) | 2011-07-31 |
Family
ID=40227837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110470T HRP20110470T1 (hr) | 2007-10-12 | 2011-06-24 | Inhibitori proteinskih kinaza |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8716296B2 (fr) |
| EP (1) | EP2212297B1 (fr) |
| JP (2) | JP5681855B2 (fr) |
| KR (1) | KR20100090772A (fr) |
| CN (2) | CN104151293A (fr) |
| AT (1) | ATE510827T1 (fr) |
| AU (1) | AU2008309517B2 (fr) |
| BR (1) | BRPI0818543A2 (fr) |
| CA (1) | CA2702008A1 (fr) |
| DK (1) | DK2212297T3 (fr) |
| EA (1) | EA020439B1 (fr) |
| HK (2) | HK1150052A1 (fr) |
| HR (1) | HRP20110470T1 (fr) |
| IL (1) | IL204594A (fr) |
| MX (1) | MX2010003987A (fr) |
| NZ (1) | NZ584454A (fr) |
| SI (1) | SI2212297T1 (fr) |
| WO (1) | WO2009047359A1 (fr) |
| ZA (1) | ZA201001910B (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
| US20110230497A1 (en) * | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| US9155724B2 (en) | 2010-02-05 | 2015-10-13 | Whitehead Institute For Biomedical Research | Combination methods for treatment of disease |
| AU2011226073B2 (en) * | 2010-03-10 | 2015-05-28 | Astrazeneca Ab | 4-Phenyl pyridine analogues as protein kinase inhibitors. |
| JP2013107824A (ja) * | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
| WO2011146313A1 (fr) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Composés de pyrazolopyrimidine pour le traitement du cancer |
| MX340490B (es) * | 2010-07-13 | 2016-07-11 | F Hoffmann-La Roche Ag * | Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| EP2668162A1 (fr) * | 2011-01-28 | 2013-12-04 | Novartis AG | Composés bi-hétéroaryles substitués en tant qu'inhibiteurs de cdk9 et leurs utilisations |
| WO2012101064A1 (fr) * | 2011-01-28 | 2012-08-02 | Novartis Ag | Composés à base de n-acyl-pyrimidine-biaryl convenant comme inhibiteurs de protéine kinase |
| EP2562265A1 (fr) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Sensibilité à des inhibiteurs sélectifs de CDK9 |
| EP2561867A1 (fr) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Inhibiteurs de CDK9 pour le traitement du carcinome de la ligne médiane |
| CA2850617A1 (fr) | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Composes pyrrolopyrimidines pour le traitement du cancer |
| US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| RU2638540C1 (ru) | 2012-04-24 | 2017-12-14 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
| WO2013177168A1 (fr) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Composés pyrimidines pour le traitement du cancer |
| WO2014062774A1 (fr) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Composés pyrazolopyrimidines pour le traitement du cancer |
| EP2925752A4 (fr) | 2012-11-27 | 2016-06-01 | Univ North Carolina | Composés à base de pyrimidine utilisables à des fins de traitement du cancer |
| HRP20211855T1 (hr) | 2013-03-12 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Inhibitori dnk-pk |
| CN105026393A (zh) | 2013-03-13 | 2015-11-04 | 艾伯维公司 | Cdk9激酶抑制剂 |
| JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系ｃｄｋ９キナーゼ阻害薬 |
| TW201446763A (zh) | 2013-03-14 | 2014-12-16 | Abbvie Inc | 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑 |
| CA2905935A1 (fr) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase |
| WO2014160028A1 (fr) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Inhibiteurs de pyrrolopyrimidine cdk9 kinase |
| GB2513403A (en) * | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| WO2015119712A1 (fr) | 2014-02-06 | 2015-08-13 | Abbvie Inc. | Inhibiteurs tétracycliques de la kinase cdk9 |
| WO2015157125A1 (fr) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Utilisations thérapeutiques de composés pyrazolopyrimidine sélectionnés présentant une activité anti-tyrosine kinase mer |
| SI3145929T1 (sl) | 2014-05-23 | 2021-10-29 | Hoffmann La Roche | 5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze |
| WO2016061144A1 (fr) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Utilisation d'inhibiteurs de cdk9 et d'inhibiteurs de brd4 pour inhiber une inflammation |
| US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| DK3313838T3 (da) | 2015-06-29 | 2019-06-11 | Astrazeneca Ab | Polycykliske amidderivater som cdk9-inhibitorer |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| CN108884070B (zh) * | 2016-04-07 | 2021-07-02 | 葛兰素史克知识产权第二有限公司 | 作为溴结构域抑制剂的吡啶基衍生物 |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
| EP3804724B1 (fr) | 2016-10-20 | 2022-12-07 | Pfizer Inc. | Inhibiteurs de cdk pour le traitement de la htap |
| US11446298B2 (en) | 2017-05-18 | 2022-09-20 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| TW201902896A (zh) | 2017-05-22 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療化合物及組合物及其使用方法 |
| EP3632907B1 (fr) * | 2017-05-24 | 2024-02-28 | Abbisko Therapeutics Co., Ltd. | Dérivé de n-(azaaryl)cyclolactame-1-carboxamide, son procédé de préparation et son utilisation |
| EP4074699A4 (fr) | 2019-12-09 | 2024-01-03 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | Composé utile en tant qu'inhibiteur de la kinase 9 dépendante de la cycline et son utilisation |
| RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| CN115448874A (zh) * | 2021-06-09 | 2022-12-09 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
| CN115703760A (zh) * | 2021-08-11 | 2023-02-17 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0108611A (pt) | 2000-02-25 | 2003-05-06 | Hoffmann La Roche | Moduladores de receptor de adenosina |
| DE10114138C2 (de) | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
| DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
| DE10129028A1 (de) | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| CN101468965A (zh) | 2003-03-24 | 2009-07-01 | 默克公司 | 联芳基取代的6元杂环钠通道阻滞剂 |
| GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| EP1648875A1 (fr) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines utilisees comme inhibiteurs de kinases |
| WO2005012298A1 (fr) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Derives de pyridinylamino-pyrimidine utiles comme inhibiteurs de la proteine kinase |
| WO2005026129A1 (fr) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases |
| US20070099938A1 (en) | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
| EP1753735A1 (fr) | 2004-04-20 | 2007-02-21 | Transtech Pharma, Inc. | Derives de thiazole et de pyrimidine substitues, modulateurs des recepteurs de la melanocortine |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| WO2006125616A2 (fr) * | 2005-05-25 | 2006-11-30 | Ingenium Pharmaceuticals Ag | Methodes de traitement de la douleur |
-
2008
- 2008-10-13 EP EP08838451A patent/EP2212297B1/fr not_active Not-in-force
- 2008-10-13 CA CA2702008A patent/CA2702008A1/fr not_active Abandoned
- 2008-10-13 US US12/226,286 patent/US8716296B2/en not_active Expired - Fee Related
- 2008-10-13 SI SI200830286T patent/SI2212297T1/sl unknown
- 2008-10-13 KR KR1020107010451A patent/KR20100090772A/ko not_active Application Discontinuation
- 2008-10-13 AU AU2008309517A patent/AU2008309517B2/en not_active Ceased
- 2008-10-13 DK DK08838451.6T patent/DK2212297T3/da active
- 2008-10-13 JP JP2010528428A patent/JP5681855B2/ja not_active Expired - Fee Related
- 2008-10-13 EA EA201000554A patent/EA020439B1/ru not_active IP Right Cessation
- 2008-10-13 BR BRPI0818543A patent/BRPI0818543A2/pt not_active IP Right Cessation
- 2008-10-13 CN CN201410394966.8A patent/CN104151293A/zh active Pending
- 2008-10-13 MX MX2010003987A patent/MX2010003987A/es active IP Right Grant
- 2008-10-13 AT AT08838451T patent/ATE510827T1/de not_active IP Right Cessation
- 2008-10-13 NZ NZ584454A patent/NZ584454A/en not_active IP Right Cessation
- 2008-10-13 WO PCT/EP2008/063715 patent/WO2009047359A1/fr active Application Filing
- 2008-10-13 CN CN200880119493.3A patent/CN101889004B/zh not_active Expired - Fee Related
-
2010
- 2010-03-17 ZA ZA2010/01910A patent/ZA201001910B/en unknown
- 2010-03-18 IL IL204594A patent/IL204594A/en not_active IP Right Cessation
-
2011
- 2011-04-27 HK HK11104221.0A patent/HK1150052A1/xx not_active IP Right Cessation
- 2011-06-24 HR HR20110470T patent/HRP20110470T1/hr unknown
-
2014
- 2014-05-05 US US14/269,703 patent/US20150038516A1/en not_active Abandoned
- 2014-09-03 JP JP2014178745A patent/JP2015038077A/ja active Pending
-
2015
- 2015-05-13 HK HK15104540.0A patent/HK1203950A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL204594A (en) | 2013-12-31 |
| AU2008309517B2 (en) | 2013-03-14 |
| AU2008309517A1 (en) | 2009-04-16 |
| CA2702008A1 (fr) | 2009-04-16 |
| JP5681855B2 (ja) | 2015-03-11 |
| SI2212297T1 (sl) | 2011-09-30 |
| IL204594A0 (en) | 2010-11-30 |
| HK1150052A1 (en) | 2011-10-28 |
| CN101889004B (zh) | 2014-09-10 |
| EP2212297B1 (fr) | 2011-05-25 |
| EA020439B1 (ru) | 2014-11-28 |
| WO2009047359A1 (fr) | 2009-04-16 |
| JP2011500539A (ja) | 2011-01-06 |
| CN101889004A (zh) | 2010-11-17 |
| ZA201001910B (en) | 2011-05-25 |
| BRPI0818543A2 (pt) | 2018-10-23 |
| MX2010003987A (es) | 2010-08-04 |
| EA201000554A1 (ru) | 2011-04-29 |
| HK1203950A1 (en) | 2015-11-06 |
| CN104151293A (zh) | 2014-11-19 |
| US20100249149A1 (en) | 2010-09-30 |
| EP2212297A1 (fr) | 2010-08-04 |
| JP2015038077A (ja) | 2015-02-26 |
| KR20100090772A (ko) | 2010-08-17 |
| US20150038516A1 (en) | 2015-02-05 |
| US8716296B2 (en) | 2014-05-06 |
| DK2212297T3 (da) | 2011-09-05 |
| ATE510827T1 (de) | 2011-06-15 |
| NZ584454A (en) | 2011-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110470T1 (hr) | Inhibitori proteinskih kinaza | |
| JP2011500539A5 (fr) | ||
| JP6636673B2 (ja) | ＳＴＩＮＧアゴニストとしてのベンゾ［ｂ］チオフェン化合物 | |
| KR101149323B1 (ko) | 8-하이드록시 퀴놀린 유도체 | |
| Yoshida et al. | MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate | |
| ES2305744T3 (es) | Derivados de quinazolina como inhibidores e tgf-beta. | |
| KR100423778B1 (ko) | 항미생물성 퀴놀론, 그의 조성물 및 용도 | |
| JP2023144075A (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物 | |
| CA2876945C (fr) | Inhibiteurs de 1,2,4-triazine-6-carboxamide kinase | |
| CN110049982A (zh) | 杂环fxr调节剂 | |
| ES2271464T3 (es) | Derivados de diazepan utiles como inhibidor del factor x. | |
| KR101435729B1 (ko) | 함질소 헤테로 고리 화합물 및 그의 염, 그리고 농원예용 살균제 | |
| TW201718494A (zh) | 吡啶酮化合物及以吡啶酮化合物作為有效成分的農園藝用殺菌劑 | |
| CA2966759C (fr) | Derives heterocycliques pour traiter des maladies associees a l'activation de la proteine stat3 | |
| AR045261A1 (es) | Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores | |
| AR098673A1 (es) | Herbicidas de pirrolidinona | |
| IL184687A0 (en) | Pharmaceutical compositions containing 1,2-dihydropyridin-2-one derivatives | |
| CO6220970A2 (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos | |
| AU2005245389A1 (en) | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | |
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| WO1992009586A1 (fr) | Inhibiteur d'oxygene actif | |
| JP6096673B2 (ja) | ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびその治療的使用 | |
| NO20074718L (no) | BCRP/ABCG2 inhibitor | |
| JP5147237B2 (ja) | 抗感染剤としてのイソチアゾロキノロン類および関連化合物 | |
| EA200700166A1 (ru) | 4-замещённые производные хинолина, способ получения и промежуточные вещества для их приготовления и содержащие их фармацевтические композиции |